Arbutus to Present at Jefferies London Healthcare Conference

Rhea-AI Summary

Arbutus Biopharma Corporation (ABUS) announced their participation in the Jefferies London Healthcare Conference on November 15, 2023, presenting their efforts in developing a cure for chronic hepatitis B virus (cHBV) infection. The live webcast of the presentation can be accessed at https://investor.arbutusbio.com/events-presentations.

WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:

Jefferies London Healthcare Conference: Formal presentation on Wednesday, November 15, 2023 at 11:30 am GMT / 6:30 am EDT.

To access the live webcast of the presentation please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

What is the event Arbutus Biopharma Corporation is participating in?

Arbutus Biopharma Corporation is participating in the Jefferies London Healthcare Conference on November 15, 2023.

What is the focus of Arbutus Biopharma Corporation's presentation at the conference?

The focus of the presentation is on Arbutus's efforts to develop a cure for chronic hepatitis B virus (cHBV) infection.

Where can the live webcast of the presentation be accessed?

The live webcast of the presentation can be accessed at https://investor.arbutusbio.com/events-presentations.